204 related articles for article (PubMed ID: 30222980)
1. Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects.
Mansour RM; Ahmed MAE; El-Sahar AE; El Sayed NS
Toxicol Appl Pharmacol; 2018 Nov; 358():76-85. PubMed ID: 30222980
[TBL] [Abstract][Full Text] [Related]
2. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury.
Zhou C; Shi X; Huang H; Zhu Y; Wu Y
Anesth Analg; 2014 May; 118(5):1090-6. PubMed ID: 24686047
[TBL] [Abstract][Full Text] [Related]
3. Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.
Hedya SA; Safar MM; Bahgat AK
Mol Neurobiol; 2018 Sep; 55(9):7579-7587. PubMed ID: 29429051
[TBL] [Abstract][Full Text] [Related]
4. Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions.
Michel HE; Tadros MG; Esmat A; Khalifa AE; Abdel-Tawab AM
Mol Neurobiol; 2017 Sep; 54(7):4866-4878. PubMed ID: 27514753
[TBL] [Abstract][Full Text] [Related]
5. Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease.
Balakrishnan R; Vijayraja D; Mohankumar T; Manimaran D; Ganesan P; Choi DK; Elangovan N
J Chem Neuroanat; 2021 Mar; 112():101890. PubMed ID: 33220427
[TBL] [Abstract][Full Text] [Related]
6. Effect of montelukast in experimental model of Parkinson's disease.
Nagarajan VB; Marathe PA
Neurosci Lett; 2018 Aug; 682():100-105. PubMed ID: 29885451
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
Abdelsalam RM; Safar MM
J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913
[TBL] [Abstract][Full Text] [Related]
8. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
9. Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.
Sener G; Sakarcan A; Sehirli O; Ekşioğlu-Demiralp E; Sener E; Ercan F; Gedik N; Yeğen BC
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):257-67. PubMed ID: 17499745
[TBL] [Abstract][Full Text] [Related]
10. Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1.
Zhang XY; Chen L; Yang Y; Xu DM; Zhang SR; Li CT; Zheng W; Yu SY; Wei EQ; Zhang LH
Brain Res; 2014 Jul; 1572():59-71. PubMed ID: 24858057
[TBL] [Abstract][Full Text] [Related]
11. Xanthotoxin modulates oxidative stress, inflammation, and MAPK signaling in a rotenone-induced Parkinson's disease model.
Sayed AS; El Sayed NS; Budzyńska B; Skalicka-Woźniak K; Ahmed MK; Kandil EA
Life Sci; 2022 Dec; 310():121129. PubMed ID: 36306871
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.
Azmy MS; Menze ET; El-Naga RN; Tadros MG
Mol Neurobiol; 2018 Aug; 55(8):6572-6588. PubMed ID: 29327204
[TBL] [Abstract][Full Text] [Related]
13. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson's disease.
Farombi EO; Awogbindin IO; Farombi TH; Oladele JO; Izomoh ER; Aladelokun OB; Ezekiel IO; Adebambo OI; Abah VO
Neurotoxicology; 2019 Jul; 73():132-141. PubMed ID: 30930291
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
[TBL] [Abstract][Full Text] [Related]
16. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation.
Zhang XY; Wang XR; Xu DM; Yu SY; Shi QJ; Zhang LH; Chen L; Fang SH; Lu YB; Zhang WP; Wei EQ
J Pharmacol Exp Ther; 2013 Aug; 346(2):328-41. PubMed ID: 23750020
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells.
Salemme A; Togna AR; Mastrofrancesco A; Cammisotto V; Ottaviani M; Bianco A; Venditti A
Brain Res Bull; 2016 Jan; 120():151-8. PubMed ID: 26592472
[TBL] [Abstract][Full Text] [Related]
18. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
[TBL] [Abstract][Full Text] [Related]
19. Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model.
Zhang D; Li S; Hou L; Jing L; Ruan Z; Peng B; Zhang X; Hong JS; Zhao J; Wang Q
J Neuroinflammation; 2021 Jan; 18(1):4. PubMed ID: 33402167
[TBL] [Abstract][Full Text] [Related]
20. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.
Saad MA; Abdelsalam RM; Kenawy SA; Attia AS
Neurochem Res; 2015 Jan; 40(1):139-50. PubMed ID: 25403620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
